In some embodiments, the formulation or composition has a viscosity of at least about 10 cP, about 20 cP, about 30 cP, about 40 cP, about 50 cP, about 60 cP, about 70 cP, about 80 cP, about 90 cP, about 100 cP, about 200 cP, about 300 cP, about 400 cP, about 500 cP, about 600 cP, about 700 cP, about 800 cP, about 900 cP, about 1,000 cP, about 2,000 cP, about 3,000 cP, about 4,000 cP, about 5,000 cP, about 6,000 cP, about 7,000 cP, about 8,000 cP, about 9,000 cP, about 10,000 cP, about 15,000 cP, or about 20,000 cP
There is no trial confirming this works as well as the full dose of both - it is a community pattern
Lastly, for consistency, we are also proposing to change the titles of MS-DRGs 124 and 125 from Other Disorders of the Eye, with and without MCC, respectively to Other Disorders of the Eye with MCC or Thrombolytic Agent, and without MCC, respectively to better reflect the assigned procedures
optimizing your clinical trials
Retroviral-mediated ectopic Ascl1 expression in the hippocampus resulted in the generation of oligodendrocytes at the expense of granule neurons [81]
Hold under tongue for 3060 seconds, then swallow